Will there be a successful human trial of a vaccine for rheumatoid arthritis by the end of 2028?
Salute e medicinaOne-Off2a
Manifold MarketsSenza KYCDati di risoluzione verificatiDiscretamente calibratoPrevisione della comunità attualeNo 79.8%
Previsori
3
Tipo di domanda
binary
Metodologia
Play-money forecasting platform
Tipo di fonte
Previsione
Dati di mercato
Aggiornato 7 minuti fa
22 mag 23, 01:52 UTC1 gen 29, 04:59 UTC
Trend
Regole
A team of researchers from the University of Toledo report that they were able to suppress the development of rheumatoid arthritis in rats by administering a vaccine containing the protein 14-3-3 zeta:
- https://www.thebrighterside.news/post/life-changing-vaccine-provides-long-lasting-protection-against-rheumatoid-arthritis
- The researchers have apparently filed for a patent for this concept and intend to pursue approval for early clinical trials in humans.
- Will their findings be reproduced in human trials?
- This will resolve YES if any clinical trial is performed to evaluate the efficacy of a vaccine for rheumatoid arthritis based on 14-3-3ζ before the end date, and the trial results show a statistically significant effect.
- Resolves NO otherwise.
